drugset / Trial / NCT03185624
Effectiveness of Rifaximin on Preventing Postoperative Recurrence in Crohn's Disease
Phase 3
Unknown
80 enrolled
Sixth Affiliated Hospital, Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University · collabPeking Union Medical College Hospital · collabRenJi Hospital · collabShanghai 10th People's Hospital · collabSir Run Run Shaw Hospital · collabXijing Hospital · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
Some studies have shown that rifaximin is effective in the management of Crohn's Disease. Meanwhile, its adverse effect is tolerable. But no study has been conducted to assess its effect on preventing postoperative recurrence. Thus, we conduct a randomised controlled study to assess the effect of rifaximin on preventing postoperative endoscopic recurrence in Crohn's disease. The primary endpoint is the rate of endoscopic recurrence at 6 months.
Timeline
- Start
- 2017-07-25
- Primary completion
- 2018-01-31
- Completion
- 2018-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifaximin | Other / unclassified | 600 mg | — |